Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
118 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01713036 | Oral Bioavailability and Mass Balance Trial With Pimasertib | completed | Phase 1 | 6 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT01288573 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | completed | Phase 1 / Phase 2 | 46 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | May 16, 2017 |
| NCT01851824 | A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | completed | Phase 1 | 9 | Hoffmann-La RocheINDUSTRY | 9 | Nov 2, 2016 | clinicaltrials |
| NCT00682981 | A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) | completed | Phase 1 / Phase 2 | 218 | Gemin XINDUSTRY | 10 | Jul 21, 2016 | clinicaltrials |
| NCT02390154 | Roniciclib Mass Balance Study | completed | Phase 1 | 7 | BayerINDUSTRY | 1 | Jul 15, 2016 | clinicaltrials |
| NCT01585649 | PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma | completed | Phase 1 | 21 | Merckle GmbHINDUSTRY | 6 | May 18, 2016 | clinicaltrials |
| NCT01008475 | EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer(POSEIDON) | completed | Phase 1 / Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 12 | Mar 30, 2016 | clinicaltrials |
| NCT01202591 | Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients(GLOW) | completed | Phase 1 / Phase 2 | 127 | AstraZenecaINDUSTRY | 8 | Feb 11, 2016 | clinicaltrials |
| NCT00900627 | Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)(THYME) | completed | Phase 1 / Phase 2 | 330 | AstraZenecaINDUSTRY | 14 | Jan 20, 2016 | clinicaltrials |
| NCT00705016 | Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)(ADVANTAGE) | completed | Phase 1 / Phase 2 | 184 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 9 | Apr 30, 2014 | clinicaltrials |
| NCT01759056 | Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis | completed | Phase 1 | 33 | Avaxia Biologics, IncorporatedINDUSTRY | 4 | Mar 5, 2014 | clinicaltrials |
| NCT01205737 | A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects | completed | Phase 1 | 186 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 10 | Oct 22, 2013 | clinicaltrials |
| NCT00785122 | IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)(IMA910-101) | completed | Phase 1 / Phase 2 | 92 | Immatics Biotechnologies GmbHINDUSTRY | 9 | May 16, 2013 | clinicaltrials |
| NCT01456065 | Safety of Active Immunotherapy in Subjects With Ovarian Cancer | unknown | Phase 1 | 15 | Life Research Technologies GmbHOTHER | 2 | Mar 1, 2013 | clinicaltrials |
| NCT00297089 | A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 165 | AbbVie (prior sponsor, Abbott)INDUSTRY | 6 | Jan 31, 2013 | clinicaltrials |
| NCT00788333 | Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer | completed | Phase 1 / Phase 2 | 40 | Bristol-Myers SquibbINDUSTRY | 5 | Jul 13, 2012 | clinicaltrials |
| NCT01023386 | A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer | completed | Phase 1 | 6 | Astellas Pharma IncINDUSTRY | 1 | Apr 13, 2010 | clinicaltrials |
| NCT00190671 | A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients | completed | Phase 1 / Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 6 | Nov 20, 2009 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials